| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |